Abstract
Five targeted agents have shown efficacy in advanced renal cell carcinoma. These agents were evaluated in pivotal phase III clinical trials using different treatment settings and different patient populations. As patients encountered in 'real life' clinical practice are frequently under-represented in phase III trials, making treatment decisions based on phase III data alone may have limitations. In order to support treatment decisions for patients who do not fit within the inclusion criteria of many phase III trials, physicians must consider additional data sources such as expanded access programmes, sub- and retrospective analyses, and also clinical experience. The suitability of a specific targeted agent for a given patient group, e.g. elderly, will depend on a number of factors, including disease-, patient- and treatment-related characteristics. Here, we identify the need for an individualised patient-focused approach to the management of advanced renal cell carcinoma in clinical practice. In order to optimise therapy for individual patients, we present a schema providing guidance on the wide range of parameters that should be considered when making treatment decisions. We recommend the integration of this approach into everyday clinical practice.
| Original language | English |
|---|---|
| Pages (from-to) | 16-23 |
| Number of pages | 8 |
| Journal | Cancer Treatment Reviews |
| Volume | 36 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Feb 2010 |
Fingerprint
Keywords
- Bevacizumab
- Everolimus
- Patient-focused
- Renal cell carcinoma
- Sorafenib
- Sunitinib
- Targeted agent
- Temsirolimus
- Treatment approach
ASJC Scopus subject areas
- Oncology
- Radiology Nuclear Medicine and imaging
Cite this
Treating the individual : The need for a patient-focused approach to the management of renal cell carcinoma. / Porta, Camillo; Bellmunt, Joaquim; Eisen, Tim; Szczylik, Cezary; Mulders, Peter.
In: Cancer Treatment Reviews, Vol. 36, No. 1, 02.2010, p. 16-23.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Treating the individual
T2 - The need for a patient-focused approach to the management of renal cell carcinoma
AU - Porta, Camillo
AU - Bellmunt, Joaquim
AU - Eisen, Tim
AU - Szczylik, Cezary
AU - Mulders, Peter
PY - 2010/2
Y1 - 2010/2
N2 - Five targeted agents have shown efficacy in advanced renal cell carcinoma. These agents were evaluated in pivotal phase III clinical trials using different treatment settings and different patient populations. As patients encountered in 'real life' clinical practice are frequently under-represented in phase III trials, making treatment decisions based on phase III data alone may have limitations. In order to support treatment decisions for patients who do not fit within the inclusion criteria of many phase III trials, physicians must consider additional data sources such as expanded access programmes, sub- and retrospective analyses, and also clinical experience. The suitability of a specific targeted agent for a given patient group, e.g. elderly, will depend on a number of factors, including disease-, patient- and treatment-related characteristics. Here, we identify the need for an individualised patient-focused approach to the management of advanced renal cell carcinoma in clinical practice. In order to optimise therapy for individual patients, we present a schema providing guidance on the wide range of parameters that should be considered when making treatment decisions. We recommend the integration of this approach into everyday clinical practice.
AB - Five targeted agents have shown efficacy in advanced renal cell carcinoma. These agents were evaluated in pivotal phase III clinical trials using different treatment settings and different patient populations. As patients encountered in 'real life' clinical practice are frequently under-represented in phase III trials, making treatment decisions based on phase III data alone may have limitations. In order to support treatment decisions for patients who do not fit within the inclusion criteria of many phase III trials, physicians must consider additional data sources such as expanded access programmes, sub- and retrospective analyses, and also clinical experience. The suitability of a specific targeted agent for a given patient group, e.g. elderly, will depend on a number of factors, including disease-, patient- and treatment-related characteristics. Here, we identify the need for an individualised patient-focused approach to the management of advanced renal cell carcinoma in clinical practice. In order to optimise therapy for individual patients, we present a schema providing guidance on the wide range of parameters that should be considered when making treatment decisions. We recommend the integration of this approach into everyday clinical practice.
KW - Bevacizumab
KW - Everolimus
KW - Patient-focused
KW - Renal cell carcinoma
KW - Sorafenib
KW - Sunitinib
KW - Targeted agent
KW - Temsirolimus
KW - Treatment approach
UR - http://www.scopus.com/inward/record.url?scp=74849131638&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=74849131638&partnerID=8YFLogxK
U2 - 10.1016/j.ctrv.2009.09.001
DO - 10.1016/j.ctrv.2009.09.001
M3 - Article
C2 - 19819078
AN - SCOPUS:74849131638
VL - 36
SP - 16
EP - 23
JO - Cancer Treatment Reviews
JF - Cancer Treatment Reviews
SN - 0305-7372
IS - 1
ER -